Related Experiment Videos
[The vaccination of children with severe somatic pathology]
V F Uchaĭkin1, L O Skachkova, O V Shamsheva
1Russian State Medical University, Center of Vaccinoprophylaxis Diavaks, Moscow, Russia.
Insights
Vaccinating children with somatic pathology is safe, with no severe complications observed. Reactions in these children were similar to those in healthy children, indicating vaccine safety for diverse pediatric populations.
Area of Science:
- Pediatrics
- Immunology
- Public Health
Background:
- Vaccination is crucial for child health.
- Concerns exist regarding vaccine safety in children with pre-existing health conditions (somatic pathology).
- Understanding vaccine reactions in this population is vital for public health policy.
Purpose of the Study:
- To assess the safety and reactogenicity of various vaccines in children with somatic pathology.
- To compare vaccine reactions in children with and without somatic pathology.
- To evaluate the impact of vaccine component load on adverse events.
Main Methods:
- A cohort of 1,696 children was vaccinated, including 1,487 with somatic pathology and 209 healthy controls.
- Vaccines used included those for diphtheria, tetanus, polio, hepatitis B, and measles, mumps, rubella from various global manufacturers.
- Adverse events and reactions were monitored and compared between the two groups.
Main Results:
- No severe vaccine-associated complications were reported in any child.
- The frequency and severity of reactions in children with somatic pathology did not significantly differ from healthy children.
- Increasing the number of vaccine components did not correlate with an increased incidence or severity of side effects.
Conclusions:
- Vaccination is demonstrated to be safe for children with various forms of somatic pathology, including CNS lesions, tumors, congenital defects, and allergic diseases.
- The safety profile of routine childhood immunizations is maintained in children with underlying health conditions.
- Current vaccination schedules are well-tolerated and do not pose increased risks for children with somatic pathology.
Abstract:
1,696 children were vaccinated; of these, 1,487 children had different kinds of somatic pathology, including 1,181 children with CNS lesions, 29 children with malignant tumors, 45 children with congenital defects, 82 children with allergic diseases, etc. The group of relatively healthy vaccinees consisted of 209 children. The following vaccines were used for immunization: Tetracoq 05, D.T.Vax, Rudivax, Imovax Polio, Vaxigrip (Pasteur Mèrieux Connaught, France); HBVax, MMRII (Merck Sharp & Dohme, USA); as well as vaccines against hepatitis B produced by Smith Kline Beecham (UK) and Combiotech (Russia). In no case severe vaccine-associated complications were observed. The frequency and manifestation of reactions in children with somatic pathology did nor essentially differ from those in relatively healthy children. The increase of the number of vaccine components did not lead to the increase of the number of side effects of the severity of their manifestation. These investigations demonstrated the safety of vaccination for children with somatic pathology.